NCT02835222View on ClinicalTrials.gov

Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

February 2, 2018

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Untreated Adult Acute Myeloid Leukemia
Interventions
DRUG

Cytarabine

Given IV

DRUG

Daunorubicin Hydrochloride

Given IV

DRUG

Selinexor

Given PO

Trial Locations (2)

23298

RECRUITING

Virginia Commonwealth University Massey Cancer Center, Richmond

27157

RECRUITING

Comprehensive Cancer Center of Wake Forest University, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER